RECRUITING

HEARTS Trial for Thoracic Cancers

Description

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires

Conditions

Non-Small Cell Lung Cancer (Stage III)Esophageal Cancer Stage I-IIIEsophagogastric Cancer Stage I-IIIThymoma and Thymic Carcinoma Stage II-IIIOther Cancers in the Thoracic Region
Talk to us

Related Conditions:

Non-Small Cell Lung Cancer (Stage III)Esophageal Cancer Stage I-IIIEsophagogastric Cancer Stage I-IIIThymoma and Thymic Carcinoma Stage II-IIIOther Cancers in the Thoracic Region

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires

The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers

HEARTS Trial for Thoracic Cancers

Condition
Non-Small Cell Lung Cancer (Stage III)
Intervention / Treatment

-

Contacts and Locations

Madison

University of Wisconsin - Madison, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \> 18 years at the time of consent.
  • * Dosimetric eligibility criteria met using endpoints from QUANTEC (\>10% of heart receives \> 25 Gy) as determined through rapid auto-planning
  • * Participants with histologically or cytologically proven AJCC, 8th edition including:
  • * Stage IIIA,IIIB, or IIIC non-operable non-small cell lung cancer
  • * Stage I-III N0-2 disease esophageal/esophagogastric cancer
  • * Stage II or III thymoma/thymic carcinoma
  • * Other cancers in the thoracic region that meet the dosimetric and other clinical trial criteria.
  • * Participants must have a definitive course of daily fractionated RT planned of at least 15 treatment fractions, typically ranging from 1.8 to 4 Gy/fraction
  • * Definitive clinical or radiologic evidence of metastatic disease with life expectancy \<12 months
  • * Prior thoracic radiotherapy significantly overlapping the heart region
  • * Contraindications to MRI
  • * Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Carri Glide-Hurst, PhD, DABR, FAAPM, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2029-03